购物车
- 全部删除
- 您的购物车当前为空
GSK-626616 是一种口服具有活力的 DYRK3抑制剂 (IC50:0.7 nM)。它以相似的效力抑制 DYRK 家族的其他成员,可用于研究贫血。
为众多的药物研发团队赋能,
让新药发现更简单!
GSK-626616 是一种口服具有活力的 DYRK3抑制剂 (IC50:0.7 nM)。它以相似的效力抑制 DYRK 家族的其他成员,可用于研究贫血。
规格 | 价格 | 库存 | 数量 |
---|---|---|---|
1 mg | ¥ 357 | 现货 | |
5 mg | ¥ 933 | 现货 | |
10 mg | ¥ 1,580 | 现货 | |
25 mg | ¥ 3,120 | 现货 | |
50 mg | ¥ 4,580 | 现货 | |
100 mg | ¥ 6,530 | 现货 | |
1 mL x 10 mM (in DMSO) | ¥ 1,090 | 现货 |
产品描述 | GSK-626616 is a potent and orally bioavailable DYRK3 inhibitor (IC50: 0.7 nM). It inhibits other members of the DYRK family with similar potency. GSK-626616 is a potential therapy for the treatment of anemia. |
靶点活性 | β-glucuronidase:0.7 nM |
体外活性 | GSK-626616 (serum-deprived HeLa cells) reduces EGF-induced phosphorylation of PRAS40 at Thr246. GSK-626616 enhances the binding of PRAS40 to mTORC1[2]. GSK-626616 abolishes the phosphorylation of S6K1 at Thr389 in nonstimulated HeLa cells. GSK-626616 reduces the phosphorylation of S6K1 at Thr389 in EGF- and insulin-stimulated HeLa cells, showing that mTORC1 activity is impaired[2]. |
分子量 | 401.27 |
分子式 | C18H10Cl2N4OS |
CAS No. | 1025821-33-3 |
存储 | Powder: -20°C for 3 years | In solvent: -80°C for 1 year | Shipping with blue ice. | |||||||||||||||||||||||||||||||||||
溶解度信息 | DMSO: 49 mg/mL (122.11 mM), Sonication is recommended. | |||||||||||||||||||||||||||||||||||
溶液配制表 | ||||||||||||||||||||||||||||||||||||
DMSO
|
版权所有©2015-2024 TargetMol Chemicals Inc.保留所有权利.